SPL 1.60% 9.6¢ starpharma holdings limited

Dep Irinotecan slide deck, page-2

  1. 3,351 Posts.
    lightbulb Created with Sketch. 793
    I assume the slide deck will also state that ‘further clinical development of DEP-Irinotecan is justified’

    But just who is going to pay for and conduct the necessary extensive and expensive Phase 3 trial given that Pfizer are disinterested in licencing despite years of Starpharma showing them trial data.


    ‘Starpharma's Dep Irinotecan combination cancer drug has shown to be superior to Onivyde’
    ~ @antibotter

    This type of misleading pumping just never stops. The forum still awaits your explanation for posting this.
    Last edited by sarge17: 04/06/24
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.